Applying the ASCO and European Society for Medical Oncology Value Frameworks to Nasopharyngeal Cancer Treatments: Is Adding Induction Chemotherapy or Adjuvant Chemotherapy to Concurrent Chemoradiotherapy Worthwhile?

Abstract

PURPOSE To determine and compare the incremental clinical benefit (ICB) and costs of induction chemotherapy (IC) when added to concurrent chemoradiotherapy (CCRT), concurrent chemotherapy (CC) when added to radiotherapy (RT), and CC plus adjuvant chemotherapy (AC) when added to RT for locally advanced nasopharyngeal cancer (LA-NPC). MATERIALS AND METHODS We searched phase III randomized controlled trials (RCTs) that reported overall survival benefit with the use of IC, CC, and CC 1 AC in LA-NPC. We quantified the ICB using the ASCO and European Society for Medical Oncology (ESMO) value frameworks. We calculated the incremental drug costs in US dollars using the lowest average wholesale price reported in the Lexicomp drug database. RESULTS We identified three RCTs on IC, three RCTs on CC, and four RCTs on CC 1 AC. The ICB was judged to be grade A based on the ESMO framework. The ASCO Net Health Benefit score ranged from 17.43 to 57.39. The incremental drug costs ranged from $133.46 to $626.14. There were no statistically significant differences in the mean Net Health Benefit scores (39.37 for IC v 37.61 for CC v 33.98 for CC 1 AC; P 5.89) and costs ($383 for IC v $253 for CC v $460 for CC 1 AC; P 5.27) between the three approaches. There was no statistically significant correlation between ICB and costs. CONCLUSION The magnitudes of ICB and incremental drug costs of adding of IC to CCRT, CC to RT, and CC 1 AC to RT for LA-NPC are not significantly different.